Genetic testing company 23andMe is preparing for a renewed auction of its assets after a federal judge agreed to reopen the ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of German pharma major Bayer’s (BAYN: DE) Nubeqa (darolutamide) for the treatment of adult patients with ...

AstraZeneca (LSE: AZN) has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in ...

US commercial-stage drugmaker Corcept Therapeutics (Nasdaq: CORT) has presented results from its DAZALS study of dazucorilant ...

Shares of Swedish drugmaker Camurus shot up 23% to 638.50 kronor yesterday on news of that it has entered a collaboration and license agreement with Eli Lilly, granting the US pharma major exclusive, ...

US gene therapy company RegeNXBio (Nasdaq: RGNX) yesterday announced new positive interim data from the Phase I/II AFFINITY ...

The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for locally advanced or metastatic renal ...

German genetic medicine company ViGeneron has announced a rebrand to become VeonGen Therapeutics. The privately-held firm has ...

San Jose, USA-based biotech Allay Therapeutics today announced the completion of a $57.5 million Series D financing round ...

US rare disease meds developer Sarepta Therapeutics (Nasdaq: SRPT) revealed that its rAAVrh74 viral vector used in the ...

US biopharma Cullinan Therapeutics has entered into an agreement with Genrix Bio for an all-indication, exclusive license to ...

AI-enabled biotech Juvenescence today announced the acquisition of Ro5 Inc, a proprietary AI drug discovery company. This ...